Equities

iZafe Group AB

iZafe Group AB

Actions
  • Price (SEK)0.24
  • Today's Change0.008 / 3.45%
  • Shares traded477.52k
  • 1 Year change+13.74%
  • Beta0.3347
Data delayed at least 15 minutes, as of Jul 04 2024 17:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

iZafe Group AB, formerly MediRatt AB, is a Sweden-based company that conducts research, development and marketing of medical products for medication and drug management. Its offering includes Dosell, a patented drug dispenser under development that can be used when medicating patients at home via remote monitoring; and MediKoll, an app that provides patients information about side effects, reactions and allergies linked to different types of medication. The Company operates in the pharmaceutical industry, hospitals and care homes, and Pharmacies and private healthcare markets. It is active globally.

  • Revenue in SEK (TTM)5.00m
  • Net income in SEK-32.78m
  • Incorporated2008
  • Employees7.00
  • Location
    iZafe Group ABSodra Fiskartorpsvagen 20STOCKHOLM 114 33SwedenSWE
  • Phone+46 8211121
  • Fax+46 87656633
  • Websitehttps://izafe.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Miris Holding AB (publ)16.26m-11.31m34.44m10.00------2.12-0.2734-0.27340.393-0.12860.8539-0.11297.341,625,800.00-59.40-59.61-186.31-111.08102.1286.68-69.57-103.610.2251-11.97-----17.192.53-20.86------
Invent Medic Sweden AB6.91m-8.34m36.18m8.00--10.49--5.24-0.2176-0.21760.17980.08010.56732.143.79863,296.30-68.50-97.56-109.24-121.0677.2677.16-120.76-490.980.4874-16.360.3007--115.97177.5328.77---22.61--
Inhalation Sciences Sweden AB18.19m-3.27m44.44m8.00--3.66--2.44-0.21-0.211.320.80141.160.94137.492,273,250.00-20.80-27.93-35.65-43.8281.2571.13-17.96-48.022.68-2.920.071--43.5526.3360.87------
Scandinavian ChemoTech AB4.11m-19.26m47.71m6.00--4.69--11.60-1.28-1.280.26410.4240.23270.32241.36685,500.00-108.95-87.29-108.95-118.5539.00252.05-468.27-2,122.77---15.730.00--496.6219.137.28------
iZafe Group AB5.00m-32.78m63.80m7.00--2.93--12.75-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
Codelab Capital AS-99.37bn-99.37bn65.92m200.00--0.4739----------0.633----------------------------0.00--------------
ProstaLund AB20.12m-18.55m68.09m6.00--0.8012--3.38-0.2436-0.24360.26380.6340.39120.432511.14---36.07-29.14-40.73-35.0171.0575.26-92.21-68.941.90-126.960.0255--27.5410.36-53.27--20.35--
Glycorex Transplantation AB (publ)31.00m-29.54m68.33m15.00--1.76--2.20-0.40-0.400.41970.54850.39780.72834.601,347,652.00-37.91-11.30-47.48-13.1784.7991.60-95.30-33.241.20-118.900.2046---17.04-2.15-254.06---0.5593--
Kontigo Care AB29.47m775.00k71.78m10.0068.272.0015.802.440.03280.03281.171.120.6807--7.69--1.79-0.42142.55-0.619568.8466.312.63-0.5205--4.000.093--1.8016.95-92.68--44.94--
BBS-Bioactive Bone Substitutes Oyj0.00-39.57m76.30m----1.25-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
SciBase Holding AB (publ)24.15m-55.54m78.67m26.00--2.06--3.26-0.5255-0.52550.22370.24570.30040.78634.33894,592.60-69.07-68.63-90.03-87.7769.2861.28-229.94-300.201.78--0.00--29.9327.50-28.75--5.15--
Immunovia AB (publ)1.21m-260.73m78.89m11.00--1.81--65.09-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Bio-Works Technologies AB43.90m-56.82m83.81m38.00--1.90--1.91-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
ScandiDos AB60.43m-14.65m91.22m34.00--1.65--1.51-0.3211-0.32111.320.9710.78530.55526.07---19.03-12.60-33.80-21.9378.6982.13-24.24-15.370.9148-11.58-----1.824.36-60.62---19.29--
Scandinavian Real Heart AB0.00-71.66m92.82m11.00--0.6201-----0.4709-0.47090.000.51440.00----0.00-67.22-24.27-78.30-26.81--832.41---6,070.11---701.980.0945---100.00---385.97---25.76--
Clinical Laserthermia Systems AB10.83m-70.90m94.94m7.00--0.9486--8.77-14.73-14.731.935.790.217312.584.86---144.45-123.49-259.50-312.95-392.44-1,084.16-664.90-1,625.032.06-30.970.0094--31.9935.55-12.92--18.26--
Data as of Jul 04 2024. Currency figures normalised to iZafe Group AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.